Reuters logo
BRIEF-Global Blood Therapeutics to initiate mid-stage trial for the treatment of idiopathic pulmonary fibrosis
November 28, 2016 / 2:17 PM / a year ago

BRIEF-Global Blood Therapeutics to initiate mid-stage trial for the treatment of idiopathic pulmonary fibrosis

Nov 28 (Reuters) - Global Blood Therapeutics Inc -

* Global Blood Therapeutics announces initiation of phase 2a trial of GBT440 in idiopathic pulmonary fibrosis (IPF)

* Is now conducting two clinical trials of GBT440 as potential treatment for hypoxemia in a broad range of patients with ipf

* Primary endpoint for study will be to evaluate effect of GBT440 on oxygen saturation at rest over a 90-day period

* Study will also assess safety, tolerability and pharmacokinetic profile of GBT440 in IPF patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below